title: Lack of kinin B₁ receptor potentiates leptin action in the liver.
abstract: Kinins B1 and B2 receptors (B1R and B2R) are classically associated with inflammation, but our group has recently demonstrated new roles for B1R in metabolism using a knockout model (B1 (-/-)). B1 (-/-) mice display improvement on leptin and insulin sensitivity and is protected from high fat diet (HFD)-induced obesity. Here, we evaluate the hepatic effects of the B1R ablation and its role on hepatic function. Despite no expression of hepatic B1R, HFD-induced hepatic lipid accumulation was lower than in control animals. B1 (-/-) mice also presented lower hepatic lipogenesis and SCD1 protein content in the liver. When stimulated with exogenous leptin, B1 (-/-) mice exhibited increased hepatic pJAK2. Similarly, leptin signaling was enhanced in the liver of ob/ob-B1 (-/-) mice, as demonstrated by increased levels of pSTAT3 compared to ob/ob. Plasma concentrations of intercellular adhesion molecule 1, fetuin A, leukemia inhibitory factor, tissue inhibitor of metalloprotease-1, resistin, and oncostatin M were reduced in B1 (-/-). Finally, B1 (-/-) mice have increased gene expression of hepatic B2 receptor, but no difference in leptin receptor expression. Our results show that B1 (-/-) mice are protected from non-alcoholic fatty liver disease (NAFLD) after HFD treatment. Since B1R expression was not observed in the liver after HFD, we propose that the cross talk between the adipose tissue and the liver, mainly through leptin, is an important factor contributing to the observed results. Besides that, several other inflammatory mediators already correlated with NAFLD or liver function were found to be altered in our model. Taken together, our data suggest that B1R plays an important role in hepatic steatosis development.
authors: Department of Biophysics, Federal University of São Paulo-UNIFESP/EPM, Rua Pedro de Toledo, 669, 9° andar, Vila Clementino, 04039-032 São Paulo, São Paulo, Brazil.
authors: Raphael Gomes
authors: RG
authors: Fonseca
authors: Vicencia Micheline
authors: VM
authors: Sales
authors: Eduardo
authors: E
authors: Ropelle
authors: Carlos Castilho
authors: CC
authors: Barros
authors: Lila
authors: L
authors: Oyama
authors: Silvia Saiuli Iuki
authors: SS
authors: Ihara
authors: Mário Jose Abdalla
authors: MJ
authors: Saad
authors: Ronaldo Carvalho
authors: RC
authors: Araújo
authors: João Bosco
authors: JB
authors: Pesquero
mesh_terms: D054392:Adipokines / Q000097:blood; D000818:Animals; D059305:Diet, High-Fat; D005234:Fatty Liver / Q000378:metabolism*; D020738:Leptin / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D065626:Non-alcoholic Fatty Liver Disease; D043783:Receptor, Bradykinin B1 / Q000172:deficiency* / Q000235:genetics; D043782:Receptor, Bradykinin B2 / Q000378:metabolism; D054411:Receptors, Leptin / Q000378:metabolism; D013230:Stearoyl-CoA Desaturase / Q000378:metabolism
chemical_list: D054392:Adipokines; D020738:Leptin; D043783:Receptor, Bradykinin B1; D043782:Receptor, Bradykinin B2; D054411:Receptors, Leptin; C515447:leptin receptor, mouse; C490333:Scd1 protein, mouse; D013230:Stearoyl-CoA Desaturase
references: J Biol Chem. 2004 May 21;279(21):21695-700
references: 14993225
references: Science. 2002 Jul 12;297(5579):240-3
references: 12114623
references: PLoS One. 2012;7(7):e40573
references: 22829877
references: J Mol Med (Berl). 2009 Oct;87(10):953-63
references: 19618151
references: Biol Chem. 2001 Jan;382(1):91-5
references: 11258678
references: Pharmacol Rev. 2005 Mar;57(1):27-77
references: 15734727
references: Atherosclerosis. 2011 Oct;218(2):378-85
references: 21664615
references: Hypertension. 2008 May;51(5):1352-7
references: 18347228
references: APMIS. 2011 Jul;119(7):412-20
references: 21635548
references: Br J Pharmacol. 2013 Jan;168(2):389-402
references: 22889120
references: Diabetes Metab Rev. 1989 May;5(3):271-84
references: 2656156
references: Diabetes Care. 2006 Apr;29(4):853-7
references: 16567827
references: Diabetes Obes Metab. 2012 Mar;14(3):244-53
references: 22023455
references: Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11482-6
references: 12177411
references: Biochem J. 1978 Mar 15;170(3):609-13
references: 646803
references: Science. 1995 Jul 28;269(5223):543-6
references: 7624777
references: Regul Pept. 2007 Feb 1;138(2-3):56-8
references: 17184856
references: Lab Invest. 2011 Jul;91(7):1107-17
references: 21519329
references: PLoS One. 2012;7(9):e44782
references: 23024762
references: Biochem J. 1976 Nov 15;160(2):413-6
references: 12755
references: Int Immunopharmacol. 2008 Feb;8(2):242-6
references: 18182234
references: Int Immunopharmacol. 2008 Feb;8(2):155-60
references: 18182219
references: Nature. 1997 May 8;387(6629):206-9
references: 9144295
references: Br J Pharmacol. 1995 Sep;116(1):1673-9
references: 8564236
references: Lab Invest. 2012 Oct;92(10):1419-27
references: 22868909
references: Biochem Biophys Res Commun. 2002 Oct 11;297(5):1259-63
references: 12372423
references: Biol Chem. 2006 Apr;387(4):431-6
references: 16606341
references: FASEB J. 2007 Jan;21(1):53-60
references: 17099068
references: C R Biol. 2006 Aug;329(8):570-7; discussion 653-5
references: 16860275
references: J Clin Invest. 2002 May;109(10):1345-50
references: 12021250
references: J Clin Invest. 2001 Oct;108(8):1113-21
references: 11602618
references: Diabetes. 2008 Jun;57(6):1491-500
references: 18332096
references: Aliment Pharmacol Ther. 2003 Apr;17(8):977-86
references: 12694079
references: Biol Chem. 2003 Jan;384(1):151-9
references: 12674509
references: Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8140-5
references: 10859349
references: Hepatology. 2004 Nov;40(5):1106-15
references: 15389776
references: Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E331-8
references: 18505833
references: Trends Endocrinol Metab. 2008 Dec;19(10):371-9
references: 18929493
references: Rev Physiol Biochem Pharmacol. 2003;149:39-52
references: 12811586
references: Pharmacol Rev. 1992 Mar;44(1):1-80
references: 1313585